Results of a phase III trial show that compared to methotrexate, afatinib significantly improved progression-free survival in patients with recurrent or metastatic squamous cell cancer of the head and neck. Presented at the ESMO 2014 Congress in Madrid, the Lux-Head (and) Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median ...Sunday, 28 September 2014
Progression-Free Survival in Head and Neck Cancer Improved by Afatinib
Results of a phase III trial show that compared to methotrexate, afatinib significantly improved progression-free survival in patients with recurrent or metastatic squamous cell cancer of the head and neck. Presented at the ESMO 2014 Congress in Madrid, the Lux-Head (and) Neck 1 trial showed that patients who received treatment with 40 mg/day oral afatinib had a 20% reduction in risk of progression or death compared to patients who received methotrexate, with a median ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment